#ESMO26 🚀 CLARITY-Gastric01 | Phase III

🧬 CLDN18.2+ GEC | Sone-Ve vs SOC

🏆 OS benefit:
🔹 3L+: 10.0 vs 5.0 mo (HR 0.47)
🔹 2L+: 10.6 vs 6.4 mo (HR 0.58)

🎯 ORR: 23.3% vs 13.8%
⚠️ PFS: HR 0.77 (NS)
✅ G≥3 TRAEs: 36.4% vs 44.8%

💡 Potential new SOC in 2L+!

@OncoAlert